Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on some of the most formidable challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor indicated for locally advanced or metastatic ROS1‑positive (ROS1+) non‑small cell lung cancer (NSCLC). The updated prescribing information now incorporates median duration of response (DOR) of 49.7 months in TKI‑naïve patients from the pivotal TRUST‑I study — more than four years of sustained clinical benefit and, per the company, the longest reported median DOR among FDA‑approved ROS1 TKIs.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Approval Type | Supplemental New Drug Application (sNDA) – label data update |
| Product | IBTROZI® (taletrectinib), oral next‑generation ROS1 inhibitor |
| Indication | Adults with locally advanced or metastatic ROS1+ NSCLC |
| Key Update | Median DOR of 49.7 months in TKI‑naïve patients (TRUST‑I, median follow‑up 51 months) |
| Safety | No changes to the label’s safety section; no new safety signals with extended follow‑up |
| Prior Approval | Full FDA approval granted June 2025, irrespective of line of therapy, with Priority Review and Breakthrough Therapy Designation in both first‑line and second‑line‑or‑later settings |
| Next Steps | EMA (accepted Mar 2026, standard review with full‑approval consideration) and MHRA (accepted Jun 2026) are reviewing the Marketing Authorization Application |
“The data are now in the FDA‑approved label, where physicians and patients can consult them directly,” said David Hung, MD, Founder, President and CEO of Nuvation Bio, noting that a median DOR exceeding four years gives newly diagnosed ROS1+ NSCLC patients greater clarity on how long treatment may last — and physicians additional evidence supporting initiation of IBTROZI early in the treatment course, when choice of therapy matters most.
Drug Profile & Mechanism of Action
- Molecule: Taletrectinib adipate — an oral, potent, CNS‑active, selective next‑generation ROS1 tyrosine kinase inhibitor (TKI)
- Target: ROS1 fusion oncogene; designed for central nervous system penetration, addressing the brain as the most common site of disease progression
- Differentiation: Longest reported median DOR among FDA‑approved ROS1 TKIs, with a confirmed safety profile and no new signals on extended follow‑up
- Global Brands: Marketed as IBTROZI® in the U.S.; DOVBLERON® in China (Innovent Biologics); approved in Japan (Nippon Kayaku)
- Company Pipeline: Also includes safusidenib (brain‑penetrant IDH1 inhibitor) and novel drug‑drug conjugates (DDC)
Clinical Evidence – TRUST Program
| Endpoint | Result (IBTROZI) | Comparator | Relative Benefit |
|---|---|---|---|
| Median DOR – TKI‑naïve (TRUST‑I) | 49.7 months | Not disclosed in this update | >4 years sustained benefit; longest median DOR among approved ROS1 TKIs |
| Median Follow‑Up (TRUST‑I) | 51 months | – | Highly mature dataset |
| Additional Follow‑Up Included | +14 months from TRUST‑I and TRUST‑II (data cutoff Aug 2025) | – | Many patients remain on therapy with multi‑year responses |
| Safety | No new safety signals; label safety section unchanged | – | Confirmed long‑term tolerability |
The sNDA drew on TRUST‑I (NCT04395677), a Phase II single‑arm study in China (N=173), and TRUST‑II (NCT04919811), a global Phase II single‑arm study (N=189), both with confirmed objective response rate by independent review as the primary endpoint. The updated data were presented at the 2026 AACR Annual Meeting and published simultaneously in the Journal of Clinical Oncology. The program also includes TRUST‑III (NCT06564324), a randomized Phase III study in 138 ROS1 TKI‑naïve patients in China comparing IBTROZI with crizotinib, and TRUST‑IV (NCT07154706), a Phase III placebo‑controlled adjuvant trial in resected early‑stage ROS1+ NSCLC (~180 patients across the U.S., Canada, Europe, Japan and China; primary endpoint DFS; completion expected 2030).
Market Impact & Outlook
- Disease Landscape: More than 1 million people are diagnosed with NSCLC annually worldwide; roughly 2 % harbor ROS1+ tumors. About 35 % of metastatic ROS1+ patients present with brain metastases at diagnosis, and ~50 % of previously treated patients develop CNS metastases — underscoring the value of a CNS‑active TKI with durable responses.
- Competitive Edge: A label‑embedded 49.7‑month median DOR strengthens IBTROZI’s positioning as a preferred first‑line option, supporting early initiation when treatment selection is most consequential.
- Global Commercial Footprint: Approvals in the U.S. and Japan, with Innovent commercializing DOVBLERON® in China; EU and UK regulatory reviews underway expand the potential addressable market.
- Lifecycle Expansion: TRUST‑IV extends the asset into the adjuvant early‑stage setting, potentially broadening IBTROZI’s indication well beyond metastatic disease this decade.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines (including the pending EMA and MHRA reviews), clinical outcomes of ongoing TRUST studies, and commercial expectations for IBTROZI (taletrectinib). Actual results may differ materially due to risks including regulatory decisions, trial enrollment and readout uncertainties, market adoption, and competitive dynamics. Investors should not place undue reliance on these statements.-Fineline Info & Tech
